Cybin Inc. Partners with Kernel’s Flow To Quantify Brain Activity During Therapy
According to The World Health Organization (WHO), one in four people in the world will be affected by mental or neurological disorders at some point in their lives. The COVID-19 […]
Cybin Advances Psilocybin as Treatment for Depression and Addiction
A biotechnology company focusing on psilocybin (found in several “psychedelic” mushrooms) recently announced significant advancements in treatment for depression and addiction. Cybin is a Canadian biotechnology company focusing on progressing […]